Rooted in deep data science, NeuTrace is building solutions for the Cardiac Electrophysiology (EP) community to advance research, diagnosis, and treatment for prospective patients with abnormal heart rhythms. Our solutions are driven by proprietary Artificial Intelligence (AI) and Machine Learning (ML) engines. Founded by a team of globally recognized clinicians, engineers, scientists and AI experts, we are developing innovative solutions for the treatment of heart disease, combining medical device, clinical and Silicon Valley technology expertise. With safety and efficacy at the heart of our mission, we aim to transform long-term outcomes in cardiovascular conditions by leveraging previously undiscovered data and analytical methods. NeuTrace was acquired by Anumana, Inc., a portfolio company of nference. For more information, visit www.anumana.ai.